ASPAC III 10-Q: Going-Concern Doubt, $686,872 Cash, and a Nov 12 Nasdaq Deadline
ASPC is trading near its 52-week low of $10.3 (1.5% above the low).
Summary
ASPAC III's Q3 10-Q discloses substantial doubt about its ability to continue as a going concern, with cash down to $686,872 and a $194,053 nine-month net loss, while it races a November 12, 2026 Nasdaq equity-compliance deadline that depends on closing the Bioserica merger.
Key Events · Earnings and Guidance · ASPC
-
Going-Concern Doubt Disclosed
Management states that mandatory liquidation if no Business Combination occurs, plus the need for additional financing, raise substantial doubt about the Company's ability to continue as a going concern.
-
Cash Down to $686,872
Cash fell from $871,350 at December 31, 2025 to $686,872 at September 30, 2026, with working capital of $145,186; the trust account holds $3,060,458.
-
Nine-Month Swing to Net Loss
Net loss of $194,053 for the nine months ended September 30, 2026 versus net income of $1,273,493 a year earlier, as interest income dropped to $98,155 from $1,948,362.
-
Nasdaq Equity Deadline November 12, 2026
The Company must regain the $2,500,000 stockholders' equity requirement by November 12, 2026 or face delisting notification, with its compliance plan resting on the Bioserica merger closing.
Analysis · ASPC · Real Estate & Construction
Management has attached an explicit going-concern warning to the shell company's third-quarter report: the mandatory liquidation that would follow a failed Bioserica deal, together with the need for additional financing, raises substantial doubt about the company's ability to continue as a going concern. Cash has fallen to $686,872 from $871,350 at year-end, and the nine-month result swung to a $194,053 net loss from $1,273,493 of income a year earlier as trust-account interest income collapsed to $98,155 from $1,948,362. Against that backdrop, the company still must regain Nasdaq's $2,500,000 stockholders' equity requirement by November 12, 2026 — the same date its compliance extension runs out — and its own cure plan hinges on closing the $217,860,000 Bioserica merger. Shareholders did approve pushing the combination deadline to November 12, 2028 on October 19, 2026, but only 8,093 Class A shares were redeemed for $87,815, leaving roughly $3.0 million in trust and the Sponsor holding about 76.6% of the 2,329,488 outstanding shares.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASPC was trading at $10.45 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $24.4M. The 52-week trading range was $10.30 to $63.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.